Signal from the log
Aptadir Therapeutics
40 M€ · Seed · Italy · Biotech
Aptadir Therapeutics, à Milan, développe des ARN qui empêchent la méthylation anormale de l'ADN sur un seul gène, pour rallumer un gène éteint par erreur. Son premier candidat, CAP1-FMR1, vise le syndrome de l'X fragile et n'a pas encore été testé chez l'humain. La levée en seed est menée par 4BIO Capital.
Verified
Announced on , logged by the watch of 29 September 2026.
- Operation
- Funding round
- Announced amount
- 40 M€
- Stage
- Seed
- Country
- Italy
- Sector
- Biotech
What the log says
Editorial note, in French
Communiqué ouvert, montant relu et fonds nommés.
The investors
Led by 4BIO Capital , with CDP Venture Capital , Indaco Venture Partners , XGEN Venture , CE-Ventures , Angelini Ventures , Kerna Ventures , Italian Angels for Biotech , Club degli Investitori
Provenance
Source tech-eu
Logged on 29 September 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Verified The press release was opened: amount double checked, funds named. The article remains to be written.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.